Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Genenta Science S.p.A. files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
3.7
4.69
3.39
5.34
6.47
4.81
2.7
General and administrative
0.92
0.9
2.3
5.71
5.26
4.95
3.9
Operating expenses
4.62
5.59
5.69
11
11.7
9.76
6.6
Operating income
-4.62
-5.59
-5.69
-11
-11.7
-9.76
-6.6
Other non-operating income
0.03
-0
0.16
2.57
0.09
0.85
0.07
Pre-tax income
-4.6
-5.59
-5.53
-8.48
-11.6
-8.91
-6.53
Net income
-4.6
-5.59
-5.53
-8.48
-11.6
-8.91
-6.53
EBITDA
-5.59
-5.68
-11
-11.7
-9.72
-6.58
EPS, basic
-0.37
-0.47
-0.64
EPS, diluted
-0.37
-0.47
-0.64
-0.49
-0.33
Shares, basic (weighted)
15.1
18.2
18.2
18.3
19.7
Shares, diluted (weighted)
15.1
18.2
18.2
18.3
19.7
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
15.5
37.2
29.8
3.69
4.58
5.53
Short-term investments
15.1
8.08
22.6
Other current assets
0.95
0.02
0.22
0.06
0.21
1.83
Total current assets
16.5
38.8
31.7
21.3
14.5
30
Property, plant and equipment
0.02
0.02
0.11
0.08
0.04
0.02
Intangible assets
0.09
Other non-current assets
0.95
1.24
1.6
Total assets
17.5
40
33.4
22.3
14.8
31.9
Accounts payable
0.54
0.16
1.04
Accrued liabilities
0.37
0.71
0.2
0.07
Total current liabilities
2.33
1.14
2.18
1.74
2.1
2.12
Other non-current liabilities
0.03
0.01
0
Total liabilities
2.35
1.17
2.3
1.91
2.33
10
Paid-in capital
36.6
Retained earnings
-21.5
-27
-35.5
-47.1
-56.1
-62.6
Other comprehensive income
0.23
0.09
0.17
Shareholders' equity
18.9
15.2
38.9
31.1
20.4
12.5
21.8
Total equity
18.9
15.2
38.9
31.1
20.4
12.5
21.8
Total liabilities and equity
17.5
40
33.4
22.3
14.8
31.9
Shares outstanding
18.2
18.2
18.2
18.2
18.3
23.4
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-4.6
-5.59
-5.53
-8.48
-11.6
-8.91
-6.53
Depreciation and amortization
0
0
0.01
0.04
0.04
0.03
Stock-based compensation
0.75
0.46
0.5
0.72
0.74
0.85
1.01
Change in payables
0.19
0.27
-0.38
0.88
-0.75
0.02
1.19
Cash from operations
-2.49
-6.04
-6.96
-7.42
-11.2
-6.24
-6.87
Capital expenditures
-0.02
-0.01
-0.03
-0.01
-0
-0.01
Purchases of investments
-14.9
-16.4
-33.2
Sales and maturities of investments
23.3
18.6
Cash from investing
-0.02
-0.01
-0.03
-14.9
6.88
-14.5
Stock issued
15.1
1.5
0
Cash from financing
14.8
1.39
28.7
0
0.27
22.3
Net change in cash
12.3
-4.68
21.8
-7.45
Free cash flow
-6.07
-6.97
-7.45
-11.2
-6.24
-6.88
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-38.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-28.0%
Net income / average total assets.
Return on invested capital (ROIC)
-43.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
74.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-11.2%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
7.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
115.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-1.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
12.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
7.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
2.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
14.2x
Current assets / current liabilities.
Quick ratio
13.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
13.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-€0.35
Free cash flow / diluted weighted shares.
Operating cash flow per share
-€0.35
Cash from operations / diluted weighted shares.
Book value per share
€0.93
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Was Genenta Science S.p.A. profitable in fiscal 2025?
No. It reported a net loss of €6.5M.
How much free cash flow did Genenta Science S.p.A. generate in fiscal 2025?
Cash from operations of €6.9M minus capital expenditures of €7.6K left free cash flow of -€6.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.